Company / Cash & Equivalents
Cytosorbents Corp Cash & Equivalents History
FY2011-FY2018 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$22.4M
FY2018
5-year range
$3.6M / $22.4M
FY2014-FY2018
Trend
+29.1%
vs FY2017
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $4M to $22M over the past 2 years.
Based on SEC 10-K filings.
$22M in FY2018 with a 5-year CAGR of +66.9%.
Improved from $4M to $22M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +61.4%
- 5-Year CAGR
- +66.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +66.9%, indicating consistent growth.
- In FY2018, cash & equivalents increased 29.1% year-over-year.
- Lowest cash & equivalents in the period was in FY2011.
Company context
Key Data Points
- Altman Z-Score -4.61 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2018 | $22.4M | +29.1% |
| FY2017 | $17.3M | +380.5% |
| FY2016 | $3.6M | -32.2% |
| FY2015 | $5.3M | +47.5% |
| FY2014 | $3.6M | +108.5% |
| FY2013 | $1.7M | +0.0% |
| FY2012 | $1.7M | +45.7% |
| FY2011 | $1.2M | - |
As of FY2018 · SEC 10-K · Updated Jun 24, 2026